Loading...
•
Mar 31, 2022
MindMed Q1 2022 Earnings Report
MindMed reported financial results for Q1 2022 and provided business highlights.
Key Takeaways
MindMed reported its Q1 2022 financial results, highlighting progress in advancing clinical programs for lead drug candidates, strengthening the leadership team, and securing a cash runway through key clinical readouts in 2023 and into 2024.
Advanced clinical programs for three lead drug candidates.
Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer.
Cash runway through key clinical readouts in 2023 and into 2024.
Initiated Study MMED008, a Phase 2b dose-optimization trial of MM-120 for the treatment of GAD.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...